Results 41 to 50 of about 182,514 (265)

Immune Checkpoint Inhibitor-Associated Myocarditis

JACC: Case Reports, 2020
Immune checkpoint inhibitors (ICIs) can induce immunity-related adverse events. We demonstrate the clinical use of cardiac magnetic resonance and endomyocardial biopsy in the diagnosis and subsequent monitoring of ICI-associated myocarditis, suggesting ...
Grigorios Chatzantonis, MD, Georg Evers, MD, Claudia Meier, MD, Michael Bietenbeck, PhD, Anca Florian, MD, Karin Klingel, MD, Annalen Bleckmann, MD, Ali Yilmaz, MD   +7 more
doaj   +1 more source

Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor

Clinical & Translational Immunology, 2022
Objectives Immune checkpoint inhibitors have achieved clinical success in cancer treatment, but this treatment causes immune‐related adverse events, including type 1 diabetes (T1D). Our aim was to test whether a JAK1/JAK2 inhibitor, effective at treating
Tingting Ge, Amber‐Lee Phung, Gaurang Jhala, Prerak Trivedi, Nicola Principe, David J De George, Evan G Pappas, Sara Litwak, Laura Sanz‐Villanueva, Tara Catterall, Stacey Fynch, Louis Boon, Thomas W Kay, Jonathan Chee, Balasubramanian Krishnamurthy, Helen E Thomas   +15 more
doaj   +1 more source

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy

Frontiers in Immunology, 2021
Accumulating evidence demonstrated the crucial role of gut microbiota in many human diseases, including cancer. Checkpoint inhibitor therapy has emerged as a novel treatment and has been clinically accepted as a major therapeutic strategy for cancer. Gut
Jianmin Wu, Shan Wang, Bo Zheng, Xinyao Qiu, Hongyang Wang, Hongyang Wang, Lei Chen   +6 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Unsuccessful rechallenge with nivolumab in a patient with advanced non‐small cell lung cancer who had a 6‐year complete response and treatment‐free period: Case report

Respirology Case Reports
Several predictive factors of immune checkpoint inhibitor response have been reported, but there has not been sufficient exploration of which patients benefit from immune checkpoint inhibitor rechallenge.
Toshiaki Takakura, Hiroaki Akamatsu, Atsushi Washioka, Eriko Murakami, Ryota Shibaki, Toshio Shimizu, Yasuhiro Koh, Nobuyuki Yamamoto   +7 more
doaj   +1 more source

Chronic immune checkpoint inhibitor pneumonitis

Journal for ImmunoTherapy of Cancer, 2020
Background Pneumonitis from immune checkpoint inhibitors (ICI) is a potentially fatal immune-related adverse event (irAE) from antiprogrammed death 1/programmed death ligand 1 immunotherapy. Most cases of ICI pneumonitis improve or resolve with 4–6 weeks
Julie R Brahmer, Patrick M Forde, Evan J Lipson, Jarushka Naidoo, Joanne Riemer, Daphne Wang, Janis M Taube, Cheng Ting Lin, Peter B Illei, Tricia R Cottrell, Lonny B Yarmus, K Ranh Voong, David Feller-Kopman, Hans Lee, Sonye K Danoff, Franco R D'Alessio, Karthik Suresh   +16 more
doaj   +1 more source

Therapeutic Response of Soft Tissue Sarcoma With Novel SS18-POU5F1 Fusion: A Case Report

Frontiers in Oncology, 2021
A novel SS18-POU5F1 fusion gene was recently reported in soft tissue sarcoma occurring in three adolescent and young adult patients. Herein, we firstly reported the treatment response of SS18-POU5F1 sarcoma to immune checkpoint inhibitor, angiogenesis ...
Zengjun Liu, Zengjun Liu, Hongtu Yuan, Mingyong Han   +3 more
doaj   +1 more source

Hyperosmotic stress induces PARP1‐mediated HPF1‐dependent mono(ADP‐ribosyl)ation

FEBS Letters, EarlyView.
Sorbitol‐induced hyperosmotic stress rapidly induces reversible mono(ADP‐ribosyl)ation (MARylation) on PARP1 without the signs of genotoxic signaling. We show that PARP1 autoMARylation is HPF1 dependent and forms hydroxylamine‐resistant O‐glycosidic linkages.
Anna Georgina Kopasz, Mihály Mérey, Rebeka Vásárhelyi, Ramóna Pék, Victor Imburchia, László Henn, Adrián Kószó, Nicholas D. Lakin, Ivan Ahel, Sébastien Huet, Ágnes Czibula, Gyula Timinszky   +11 more
wiley   +1 more source

Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report

Journal of Medical Case Reports, 2018
Background Novel immune checkpoint inhibitors have been often utilized for different types of malignancies as salvage therapy with varying success. One obstacle to immune checkpoint inhibitor use is the higher incidence of immune-mediated side effects ...
Linh Ngo, Eric Miller, Peter Valen, Elie Gertner   +3 more
doaj   +1 more source

Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy

Pulmonary Circulation, 2020
Immune checkpoint inhibitors successfully treat various malignancies by inducing an immune response to tumor cells. However, their use has been associated with a variety of autoimmune disorders, such as diabetes, hepatitis, and pneumonitis.
Matthew Glick, Chase Baxter, David Lopez, Kashif Mufti, Stephen Sawada, Tim Lahm   +5 more
doaj   +1 more source